Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Alternative to prophylactic pancreatic stent placement in high-risk ERCP? 

This month's issue of the American Journal of Gastroenterology exmines the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP?

News image

A recent large-scale randomized controlled trial demonstrated that rectal indomethacin administration is effective in addition to pancreatic stent placement for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk cases.

Dr Joseph Elmunzer from Michigan, USA performed a post hoc analysis of this randomized controlled trial to explore whether rectal indomethacin can replace PSP in the prevention of pancreatitis and to estimate the potential cost savings of such an approach.

The team retrospectively classified randomized controlled trial subjects into 4 prevention groups.

Group 1 included no prophylaxis, Group 2 involved pancreatic stent placement alone, Group 3 received rectal indomethacin alone, and Group 4 included the combination of pancreatic stent placement and indomethacin.

Multivariable logistic regression was used to adjust for imbalances in the prevalence of risk factors for pancreatitis between the groups.

Based on these adjusted pancreatitis rates, the research team conducted an economic analysis comparing the costs associated with pancreatitis prevention strategies employing rectal indomethacin alone, pancreatic stent placement alone, or the combination of both.

A prevention strategy employing rectal indomethacin alone could save about $150 million annually
American Journal  of  Gastroenterology

ogyAfter adjusting for risk using 2 different logistic regression models, rectal indomethacin alone appeared to be more effective for preventing  pancreatitis than no prophylaxis, pancreatic stent placement alone, and the combination of indomethacin and pancreatic stent placement .

The doctors found that indomethacin alone was a cost-saving strategy in 96% of Monte Carlo trials.

A prevention strategy employing rectal indomethacin alone could save approximately $150 million annually in the United States compared with a strategy of pancreatic stent placement alone, and $85 million compared with a strategy of indomethacin and pancreatic stent placement.

Dr Joseph's team commented, "This hypothesis-generating study suggests that prophylactic rectal indomethacin could replace pancreatic stent placement  in patients undergoing high-risk preventing post-endoscopic retrograde cholangiopancreatography, potentially improving clinical outcomes and reducing healthcare costs."

"A randomized controlled trial comparing rectal indomethacin alone vs indomethacin plus pancreatic stent placement is needed."

Am J Gastroenterol 2013; 108: 410–415
21 March 2013

Go to top of page Email this page Email this page to a colleague

 04 March 2015

Advanced search
 04 March 2015 
Progression of Barrett's
 04 March 2015 
Multidisciplinary management of rectal cancer
 04 March 2015 
Management of IBD
 03 March 2015 
Risk of anastomotic leak after colectomy
 03 March 2015 
GI bleeding in chronic kidney disease patients on aspirin
 03 March 2015 
EPHX1 polymorphism and esophageal cancer risk
 02 March 2015 
Liver disease in patients awaiting liver transplant
 02 March 2015 
Genes and early diagnosis of IBD
 02 March 2015 
Assessment of GERD
 27 February 2015 
Obesity and weight-loss therapy
 27 February 2015 
MRE performance in staging liver fibrosis
 27 February 2015 
Bleeding in diverticulosis
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Herbal products and the liver
 26 February 2015 
Questionnaires for GERD
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Prevalence of microscopic colitis
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patients’ colonoscopist selection
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 11 February 2015 
NAFLD and CVD
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD
 06 February 2015 
Colorectal cancer risk in IBD
 06 February 2015 
H. pylori and peptic ulcer bleeding
 06 February 2015 
IBS and somatization
 05 February 2015 
GERD, dyspepsia and IBS symptoms
 05 February 2015 
Thalidomide and refractory Crohn's
 05 February 2015 
Quality of life in Crohn's after antitumor necrosis factor agents

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us